Finder makes money from featured partners, but editorial opinions are our own. Advertiser Disclosure
Zymeworks Inc is a biotechnology business based in the US. Zymeworks shares (ZYME) are listed on the NYSE and all prices are listed in US Dollars. Zymeworks employs 327 staff and has a trailing 12-month revenue of around 0.00.
Our top pick for
Beginners
Our top pick for
Building a portfolio
Our top pick for
Advanced traders
| Latest market close | $5.54 |
|---|---|
| 52-week range | $4.56 - $38.63 |
| 50-day moving average | $5.96 |
| 200-day moving average | $13.18 |
| Wall St. target price | $24.45 |
| PE ratio | N/A |
| Dividend yield | $0 (0%) |
| Earnings per share (TTM) | $-4.97 |
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $5.54 from 2022-07-01
| 1 week (2022-06-27) | -9.48% |
|---|---|
| 1 month (2022-06-01) | -20.63% |
| 3 months (2022-03-31) | N/A |
| 6 months (2021-12-31) | -66.20% |
| 1 year (2021-07-02) | -84.81% |
|---|---|
| 2 years (2020-07-02) | -84.60% |
| 3 years (2019-07-03) | 23.16 |
| 5 years (2017-07-03) | 8.28 |
| Revenue TTM | $28 million |
|---|---|
| Gross profit TTM | $-172,859,000 |
| Return on assets TTM | -33.15% |
| Return on equity TTM | -72.74% |
| Profit margin | 0% |
| Book value | $4.89 |
| Market capitalisation | $320.1 million |
TTM: trailing 12 months
We're not expecting Zymeworks to pay a dividend over the next 12 months.
Over the last 12 months, Zymeworks's shares have ranged in value from as little as $4.56 up to $38.63. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NYSE average) beta is 1, while Zymeworks's is 1.0485. This would suggest that Zymeworks's shares are a little bit more volatile than the average for this exchange and represent, relatively-speaking, a slightly higher risk (but potentially also market-beating returns).
Zymeworks Inc. , a clinical-stage biopharmaceutical company, discovers, develops, and commercializes biotherapeutics for the treatment of cancer. The company's lead product candidates include zanidatamab, a novel bispecific antibody that is in Phase 1 and Phase 2 clinical trials for the treatment of biliary tract, gastroesophageal adenocarcinomas, breast, and colorectal cancer; and ZW49, a biparatopic anti-human epidermal growth factor receptor 2 (HER2) antibody-drug conjugate that is in Phase 1 clinical trial for the treatment of advanced or metastatic HER2-expressing tumors. The company has strategic partnerships with Merck Sharp & Dohme Research Ltd. ; Eli Lilly and Company; Bristol-Myers Squibb company; GlaxoSmithKline Intellectual Property Development Ltd. ; Daiichi Sankyo Co. , Ltd.
Everything we know about the Citrine Global IPO, plus information on how to buy in.
Everything we know about the Genelux Corporation IPO, plus information on how to buy in.
Everything we know about the Magic Empire Global IPO, plus information on how to buy in.
Everything we know about the Intchains Group IPO, plus information on how to buy in.
Everything we know about the Biostage IPO, plus information on how to buy in.
Everything we know about the Wang & Lee Group IPO, plus information on how to buy in.
Everything we know about the OptMed IPO, plus information on how to buy in.
Everything we know about the Lichen China IPO, plus information on how to buy in.
Everything we know about the LeeWay Services IPO, plus information on how to buy in.
Everything we know about the Nano Labs IPO, plus information on how to buy in.